Q-omics provides the consensus-scored ZIC5 profile across patient tissues and cancer cell-line models. ZIC5 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZIC5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ZIC5 RNA expression shows 13,289 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where ZIC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZIC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZIC5 survival associations across molecular data types. ZIC5 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZIC5 RNA expression–survival associations across cancer types. High ZIC5 expression shows unfavorable associations in ACC, KIRC, KIRP, MESO, KICH and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZIC5 RNA expression.
This table summarizes ZIC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZIC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZIC5 shows higher tumor expression in HNSC, LUSC, COAD, LIHC, BLCA and BRCA. The HNSC box plot shows higher ZIC5 RNA expression in tumor versus normal tissue (log2 FC = +1.830, t-test p < 0.001).
This table shows molecular features associated with ZIC5 in patient tissues and cancer cell lines. In patient samples, ZIC5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ZIC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
